{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:52:48Z","timestamp":1791921168136,"version":"4.3.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"DOI":"10.1038\/s41587-026-03310-1","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:38:05Z","timestamp":1791920285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-3948","authenticated-orcid":false,"given":"Yuang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Monkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haseeb","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9529-2522","authenticated-orcid":false,"given":"Binlong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Thadhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"McMullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Self","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Detmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lapteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4255-0492","authenticated-orcid":false,"given":"Robert","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-4798","authenticated-orcid":false,"given":"Daniel G.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"3310_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1126\/science.abq6990","volume":"378","author":"DJ Irvine","year":"2022","unstructured":"Irvine, D. J., Maus, M. V., Mooney, D. J. & Wong, W. W. The future of engineered immune cell therapies. Science 378, 853\u2013858 (2022).","journal-title":"Science"},{"key":"3310_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","volume":"25","author":"YR Li","year":"2025","unstructured":"Li, Y. R., Zhu, Y., Halladay, T. & Yang, L. In vivo CAR engineering for immunotherapy. Nat. Rev. Immunol. 25, 725\u2013744 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"3310_CR3","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"3310_CR4","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3310_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041003","volume":"15","author":"V Wang","year":"2023","unstructured":"Wang, V., Gauthier, M., Decot, V., Reppel, L. & Bensoussan, D. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers (Basel) 15, 1003 (2023).","journal-title":"Cancers (Basel)"},{"key":"3310_CR6","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N., Maus, M. V. & Hinrichs, C. S. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA 332, 1924\u20131935 (2024).","journal-title":"JAMA"},{"key":"3310_CR7","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","volume":"43","author":"A Biederstadt","year":"2025","unstructured":"Biederstadt, A. & Rezvani, K. Engineered natural killer cells for cancer therapy. Cancer Cell 43, 1987\u20132013 (2025).","journal-title":"Cancer Cell"},{"key":"3310_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3310_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"3310_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi, A. et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet 405, 127\u2013136 (2025).","journal-title":"Lancet"},{"key":"3310_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"3310_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski, T. J., Biederstadt, A. & Rezvani, K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat. Rev. Cancer 22, 557\u2013575 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"3310_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf, N. K., Kissiov, D. U. & Raulet, D. H. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat. Rev. Immunol. 23, 90\u2013105 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"3310_CR14","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett, G., Mackensen, A. & Mougiakakos, D. CAR T-cell therapy in autoimmune diseases. Lancet 402, 2034\u20132044 (2023).","journal-title":"Lancet"},{"key":"3310_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32866-0","volume":"13","author":"U Blache","year":"2022","unstructured":"Blache, U., Popp, G., Dunkel, A., Koehl, U. & Fricke, S. Potential solutions for manufacture of CAR T cells in cancer immunotherapy. Nat. Commun. 13, 5225 (2022).","journal-title":"Nat. Commun."},{"key":"3310_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_397912","volume":"43","author":"ERS Cliff","year":"2023","unstructured":"Cliff, E. R. S. et al. High cost of chimeric antigen receptor T-cells: challenges and solutions. Am. Soc. Clin. Oncol. Educ. Book 43, e397912 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"3310_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"3310_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley, M. M. et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small 20, e2304378 (2024).","journal-title":"Small"},{"key":"3310_CR19","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"3310_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/d41573-024-00150-z","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. In vivo CAR T cells move into clinical trials. Nat. Rev. Drug Discov. 23, 727\u2013730 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3310_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker, L. et al. mRNA\u2013lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).","journal-title":"Int. J. Pharm."},{"key":"3310_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02441-2","volume":"4","author":"MJ Carrasco","year":"2021","unstructured":"Carrasco, M. J. et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun. Biol. 4, 956 (2021).","journal-title":"Commun. Biol."},{"key":"3310_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4054815","volume":"2018","author":"S Matosevic","year":"2018","unstructured":"Matosevic, S. Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies. J. Immunol. Res. 2018, 4054815 (2018).","journal-title":"J. Immunol. Res."},{"key":"3310_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611163","volume":"11","author":"P Schmidt","year":"2020","unstructured":"Schmidt, P., Raftery, M. J. & Pecher, G. Engineering NK cells for CAR therapy\u2014recent advances in gene transfer methodology. Front. Immunol. 11, 611163 (2020).","journal-title":"Front. Immunol."},{"key":"3310_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02406-6","volume":"12","author":"GM Robbins","year":"2021","unstructured":"Robbins, G. M., Wang, M., Pomeroy, E. J. & Moriarity, B. S. Nonviral genome engineering of natural killer cells. Stem Cell Res. Ther. 12, 350 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"3310_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00760","volume":"8","author":"J Bi","year":"2017","unstructured":"Bi, J. & Tian, Z. NK cell exhaustion. Front. Immunol. 8, 760 (2017).","journal-title":"Front. Immunol."},{"key":"3310_CR27","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-19-2095","volume":"26","author":"L Borst","year":"2020","unstructured":"Borst, L., van der Burg, S. H. & van Hall, T. The NKG2A\u2013HLA-E axis as a novel checkpoint in the tumor microenvironment. Clin. Cancer Res. 26, 5549\u20135556 (2020).","journal-title":"Clin. Cancer Res."},{"key":"3310_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier, E. et al. Natural killer cell therapies. Nature 626, 727\u2013736 (2024).","journal-title":"Nature"},{"key":"3310_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1264562","volume":"6","author":"C Sun","year":"2017","unstructured":"Sun, C. et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology 6, e1264562 (2017).","journal-title":"Oncoimmunology"},{"key":"3310_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","volume":"20","author":"S Bournazos","year":"2020","unstructured":"Bournazos, S., Gupta, A. & Ravetch, J. V. The role of IgG Fc receptors in antibody-dependent enhancement. Nat. Rev. Immunol. 20, 633\u2013643 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"3310_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1\u201311 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"3310_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nprot.2014.177","volume":"10","author":"CE Hagemeyer","year":"2015","unstructured":"Hagemeyer, C. E. et al. Particle generation, functionalization and sortase A-mediated modification with targeting of single-chain antibodies for diagnostic and therapeutic use. Nat. Protoc. 10, 90\u2013105 (2015).","journal-title":"Nat. Protoc."},{"key":"3310_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131177","volume":"10","author":"RR Beerli","year":"2015","unstructured":"Beerli, R. R., Hell, T., Merkel, A. S. & Grawunder, U. Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency. PLoS ONE 10, e0131177 (2015).","journal-title":"PLoS ONE"},{"key":"3310_CR34","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1039\/D2BM01846B","volume":"11","author":"LE Waggoner","year":"2023","unstructured":"Waggoner, L. E., Miyasaki, K. F. & Kwon, E. J. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury. Biomater. Sci. 11, 4238\u20134253 (2023).","journal-title":"Biomater. Sci."},{"key":"3310_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nn.2467","volume":"13","author":"L Madisen","year":"2010","unstructured":"Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133\u2013140 (2010).","journal-title":"Nat. Neurosci."},{"key":"3310_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"3310_CR37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109256118","volume":"118","author":"SA Dilliard","year":"2021","unstructured":"Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3310_CR38","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899\u2013910 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3310_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41591-024-03326-7","volume":"31","author":"K Cwynarski","year":"2025","unstructured":"Cwynarski, K. et al. TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1\/2 trial. Nat. Med. 31, 137\u2013143 (2025).","journal-title":"Nat. Med."},{"key":"3310_CR40","doi-asserted-by":"crossref","unstructured":"Terziroli Beretta-Piccoli, B., Mieli-Vergani, G. & Vergani, D. Autoimmune hepatitis. Cell. Mol. Immunol. 19, 158\u2013176 (2022).","DOI":"10.1038\/s41423-021-00768-8"},{"key":"3310_CR41","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41590-022-01315-x","volume":"23","author":"J Dubrot","year":"2022","unstructured":"Dubrot, J. et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat. Immunol. 23, 1495\u20131506 (2022).","journal-title":"Nat. Immunol."},{"key":"3310_CR42","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1158\/1541-7786.MCR-20-0652","volume":"19","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Qa-1b modulates resistance to anti-PD-1 immune checkpoint blockade in tumors with defects in antigen processing. Mol. Cancer Res. 19, 1076\u20131084 (2021).","journal-title":"Mol. Cancer Res."},{"key":"3310_CR43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1074-7613(02)00258-3","volume":"16","author":"P Li","year":"2002","unstructured":"Li, P., McDermott, G. & Strong, R. K. Crystal structures of RAE-1\u03b2 and its complex with the activating immunoreceptor NKG2D. Immunity 16, 77\u201386 (2002).","journal-title":"Immunity"},{"key":"3310_CR44","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1073\/pnas.78.7.4046","volume":"78","author":"WP Jencks","year":"1981","unstructured":"Jencks, W. P. On the attribution and additivity of binding energies. Proc. Natl Acad. Sci. USA 78, 4046\u20134050 (1981).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3310_CR45","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200045R","volume":"36","author":"KE Aryee","year":"2022","unstructured":"Aryee, K. E. et al. Enhanced development of functional human NK cells in NOD-scid-IL2rgnull mice expressing human IL15. FASEB J. 36, e22476 (2022).","journal-title":"FASEB J."},{"key":"3310_CR46","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41590-023-01741-5","volume":"25","author":"NL Board","year":"2024","unstructured":"Board, N. L. et al. Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells. Nat. Immunol. 25, 462\u2013470 (2024).","journal-title":"Nat. Immunol."},{"key":"3310_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01263","volume":"10","author":"B Hervier","year":"2019","unstructured":"Hervier, B., Russick, J., Cremer, I. & Vieillard, V. NK cells in the human lungs. Front. Immunol. 10, 1263 (2019).","journal-title":"Front. Immunol."},{"key":"3310_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02050-5","volume":"10","author":"J Li","year":"2025","unstructured":"Li, J., Xiao, C., Li, C. & He, J. Tissue-resident immune cells: from defining characteristics to roles in diseases. Signal Transduct. Target. Ther. 10, 12 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3310_CR49","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","volume":"4","author":"R Basar","year":"2020","unstructured":"Basar, R., Daher, M. & Rezvani, K. Next-generation cell therapies: the emerging role of CAR-NK cells. Blood Adv. 4, 5868\u20135876 (2020).","journal-title":"Blood Adv."},{"key":"3310_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01058-z","volume":"7","author":"GH Ran","year":"2022","unstructured":"Ran, G. H. et al. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct. Target. Ther. 7, 205 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3310_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun, L., Su, Y., Jiao, A., Wang, X. & Zhang, B. T cells in health and disease. Signal Transduct. Target. Ther. 8, 235 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3310_CR52","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1182\/bloodadvances.2020001822","volume":"4","author":"E Kroeze","year":"2020","unstructured":"Kroeze, E., Loeffen, J. L. C., Poort, V. M. & Meijerink, J. P. P. T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? Blood Adv. 4, 3466\u20133473 (2020).","journal-title":"Blood Adv."},{"key":"3310_CR53","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1016\/j.immuni.2024.09.016","volume":"57","author":"N Aljobaily","year":"2024","unstructured":"Aljobaily, N. et al. Autoimmune CD4+ T cells fine-tune TCF1 expression to maintain function and survive persistent antigen exposure during diabetes. Immunity 57, 2583\u20132596 (2024).","journal-title":"Immunity"},{"key":"3310_CR54","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41423-024-01197-z","volume":"21","author":"F Arnold","year":"2024","unstructured":"Arnold, F. et al. Tissue-resident memory T cells break tolerance to renal autoantigens and orchestrate immune-mediated nephritis. Cell. Mol. Immunol. 21, 1066\u20131081 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"3310_CR55","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520\u2013531 (2018).","journal-title":"Leukemia"},{"key":"3310_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85\u2013100 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3310_CR57","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1084\/jem.20071859","volume":"205","author":"M Holdener","year":"2008","unstructured":"Holdener, M. et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J. Exp. Med. 205, 1409\u20131422 (2008).","journal-title":"J. Exp. Med."},{"key":"3310_CR58","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/nprot.2013.101","volume":"8","author":"CP Guimaraes","year":"2013","unstructured":"Guimaraes, C. P. et al. Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactions. Nat. Protoc. 8, 1787\u20131799 (2013).","journal-title":"Nat. Protoc."},{"key":"3310_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/CIRCRESAHA.111.249375","volume":"109","author":"HT Ta","year":"2011","unstructured":"Ta, H. T. et al. Enzymatic single-chain antibody tagging: a universal approach to targeted molecular imaging and cell homing in cardiovascular disease. Circ. Res. 109, 365\u2013373 (2011).","journal-title":"Circ. Res."},{"key":"3310_CR60","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1021\/bc200694t","volume":"23","author":"X Guo","year":"2012","unstructured":"Guo, X., Wu, Z. & Guo, Z. New method for site-specific modification of liposomes with proteins using sortase A-mediated transpeptidation. Bioconjug. Chem. 23, 650\u2013655 (2012).","journal-title":"Bioconjug. Chem."},{"key":"3310_CR61","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41565-022-01266-2","volume":"18","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nat. Nanotechnol. 18, 193\u2013204 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"3310_CR62","doi-asserted-by":"crossref","unstructured":"Hintermann, E., Ehser, J. & Christen, U. The CYP2D6 animal model: how to induce autoimmune hepatitis in mice. J. Vis. Exp. (60), 3644 (2012).","DOI":"10.3791\/3644-v"},{"key":"3310_CR63","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41587-023-02118-7","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. An oncolytic virus\u2013T cell chimera for cancer immunotherapy. Nat. Biotechnol. 42, 1876\u20131887 (2024).","journal-title":"Nat. Biotechnol."},{"key":"3310_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1021\/acs.jpcb.3c06662","volume":"128","author":"P Eastman","year":"2024","unstructured":"Eastman, P. et al. OpenMM 8: molecular dynamics simulation with machine learning potentials. J. Phys. Chem. B 128, 109\u2013116 (2024).","journal-title":"J. Phys. Chem. B"},{"key":"3310_CR65","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier, J. A. et al. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 11, 3696\u20133713 (2015).","journal-title":"J. Chem. Theory Comput."},{"key":"3310_CR66","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1126\/science.1187409","volume":"330","author":"DE Shaw","year":"2010","unstructured":"Shaw, D. E. et al. Atomic-level characterization of the structural dynamics of proteins. Science 330, 341\u2013346 (2010).","journal-title":"Science"},{"key":"3310_CR67","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/jcc.21787","volume":"32","author":"N Michaud-Agrawal","year":"2011","unstructured":"Michaud-Agrawal, N., Denning, E. J., Woolf, T. B. & Beckstein, O. MDAnalysis: a toolkit for the analysis of molecular dynamics simulations. J. Comput. Chem. 32, 2319\u20132327 (2011).","journal-title":"J. Comput. Chem."},{"key":"3310_CR68","doi-asserted-by":"publisher","unstructured":"Thadhani, E. NK-MD-Analysis: MD interface analysis notebooks, v1.0.0. Zenodo https:\/\/doi.org\/10.5281\/zenodo.21983910 (2026).","DOI":"10.5281\/zenodo.21983910"},{"key":"3310_CR69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-0716-2160-8_5","volume":"2463","author":"L Shan","year":"2022","unstructured":"Shan, L., Flavell, R. A. & Herndler-Brandstetter, D. Development of humanized mouse models for studying human NK cells in health and disease. Methods Mol. Biol. 2463, 53\u201366 (2022).","journal-title":"Methods Mol. Biol."},{"key":"3310_CR70","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper, M. L. et al. An \u2018off-the-shelf\u2019 fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia 32, 1970\u20131983 (2018).","journal-title":"Leukemia"},{"key":"3310_CR71","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei, W. et al. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial. Nat. Cancer 6, 786\u2013800 (2025).","journal-title":"Nat. Cancer"}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03310-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03310-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03310-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:38:07Z","timestamp":1791920287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03310-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":71,"alternative-id":["3310"],"URL":"https:\/\/doi.org\/10.1038\/s41587-026-03310-1","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.G.A. discloses potential competing interests because of his advising (past and present) for Alnylam, Sanofi, Translate Bio, CRISPR Tx, oRNA Therapeutics, Souffl\u00e9 Therapeutics and Combined Therapeutics. R.L. discloses potential competing interests because of his advising (past and present) for Alnylam, Moderna, Souffl\u00e9 Therapeutics and Combined Therapeutics. A list of entities with which R.L. is involved with, compensated or uncompensated, is available on Dropbox (\n                      \n                      ). A patent application covering aspects of this work has been filed by D.G.A., Yuang C., J.M., H.M. and R.L. (application no. 64\/059,548) and is currently pending. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}